Gitnux/Report 2026

Colonoscopy Statistics

Quality upgrades nudged colorectal cancer screening adherence up by 0.7% among adults aged 50 to 75, yet the safety picture is tight and actionable, from 0.003% procedure related mortality to outpatient same day discharge rates above 95%. You will also see what moves the needle most on detection and outcomes, including a 10% higher ADR tied to better colorectal cancer results and bowel prep quality improvements that cut inadequate prep from 25% to 15%.
44Statistics
44Sources
10Sections
8mRead
June 24, 2026Updated
Colonoscopy Statistics
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 36 days
Colonoscopy reduces colorectal cancer risk, but the tradeoffs show up in side-effect rates and performance metrics. A 0.7% absolute rise in screening adherence among adults aged 50 to 75 followed quality improvements from 2012 to 2014. Safety data also matter because 4.0% of colonoscopies in a large U.S. cohort had immediate adverse events.

Key Takeaways

  • 0.7% absolute increase in colorectal cancer screening adherence occurred among adults aged 50–75 following implementation of quality improvements (2012–2014 vs. prior period)
  • 4.0% of colonoscopies in a large U.S. endoscopy cohort were complicated by immediate adverse events
  • 0.6% risk of post-colonoscopy bleeding was reported for diagnostic and polypectomy colonoscopies in a systematic review
  • 0.003% of colonoscopies ended in procedure-related mortality in a systematic review of adverse events
  • 6% post-polypectomy bleeding rate was reported in a systematic review for all polypectomy sizes
  • Withdrawal time of at least 6 minutes is recommended as a quality indicator for colonoscopy by the U.S. Multi-Society Task Force
  • 10% higher ADR was associated with improved colorectal cancer outcomes in a large study (observational evidence summarized in peer-reviewed literature)
  • Same-day discharge rates for outpatient colonoscopy exceed 95% in U.S. ambulatory settings (observational outcomes)
  • Bowel preparation quality improvement programs reduced inadequate bowel prep from 25% to 15% in a quality improvement study
  • Water-assisted colonoscopy reduced adenoma miss rate by 50% in a randomized trial of colonoscopy techniques
  • The global colorectal cancer screening market size was $X billion in 2023
  • Endoscope reprocessing services had a global market size of $Z million in 2022
  • Colonoscopy demand is forecast to grow at a CAGR of 6.0% from 2023 to 2030 according to a market research estimate
  • 53.3% colorectal cancer screening coverage among Medicare beneficiaries aged 66–75 in 2020 (U.S. claims-based quality measure estimate), indicating how many eligible beneficiaries received screening
  • 95% or greater same-day discharge is reported across outpatient colonoscopy settings as a performance benchmark for recovery and throughput (utilization quality indicator)

Quality improvements boosted screening by 0.7% while serious colonoscopy complications remained rare.

01 · Category

Screening Coverage1 stats

01
0.7% absolute increase in colorectal cancer screening adherence occurred among adults aged 50–75 following implementation of quality improvements (2012–2014 vs. prior period)https://jamanetwork.com/journals/jama/fullarticle/2631757
Interpretation

Screening Coverage Interpretation

Within the screening coverage category, quality improvements led to a modest but measurable 0.7% absolute increase in colorectal cancer screening adherence among adults aged 50 to 75 after 2012–2014 compared with the earlier period.

02 · Category

Safety And Complications10 stats

01
4.0% of colonoscopies in a large U.S. endoscopy cohort were complicated by immediate adverse eventshttps://pubmed.ncbi.nlm.nih.gov/25406894/
02
0.6% risk of post-colonoscopy bleeding was reported for diagnostic and polypectomy colonoscopies in a systematic reviewhttps://pubmed.ncbi.nlm.nih.gov/25890908/
03
0.003% of colonoscopies ended in procedure-related mortality in a systematic review of adverse eventshttps://pubmed.ncbi.nlm.nih.gov/29504232/
04
0.5% of patients undergoing colonoscopy experienced cardiopulmonary complications in a multicenter studyhttps://pubmed.ncbi.nlm.nih.gov/22461506/
05
0.2% of colonoscopy patients were hospitalized within 7 days in a Medicare claims analysishttps://pubmed.ncbi.nlm.nih.gov/28618104/
06
0.08% of colonoscopies had post-procedure emergency department visits within 30 days in a claims-based studyhttps://pubmed.ncbi.nlm.nih.gov/30942028/
07
0.12% risk of infectious complications was found after colonoscopy in a systematic reviewhttps://pubmed.ncbi.nlm.nih.gov/30018224/
08
0.05% risk of thromboembolic events after colonoscopy was reported in a large cohort studyhttps://pubmed.ncbi.nlm.nih.gov/32049910/
09
2.3% of patients experienced sedation-related adverse events in an observational study of U.S. outpatient endoscopyhttps://pubmed.ncbi.nlm.nih.gov/25384239/
10
0.7% of patients with anticoagulation/antiplatelet therapy had bleeding complications after polypectomy in a prospective studyhttps://pubmed.ncbi.nlm.nih.gov/27914340/
Interpretation

Safety And Complications Interpretation

Safety and complications data show that most colonoscopy outcomes are uncommon but not zero, with immediate adverse events at 4.0% and bleeding and serious risks much lower at 0.6% for post-colonoscopy bleeding and 0.003% for procedure-related mortality.

03 · Category

Quality And Performance7 stats

01
6% post-polypectomy bleeding rate was reported in a systematic review for all polypectomy sizeshttps://pubmed.ncbi.nlm.nih.gov/27126831/
02
Withdrawal time of at least 6 minutes is recommended as a quality indicator for colonoscopy by the U.S. Multi-Society Task Forcehttps://www.gastrojournal.org/article/S0016-5085(15)00179-2/fulltext
03
10% higher ADR was associated with improved colorectal cancer outcomes in a large study (observational evidence summarized in peer-reviewed literature)https://pubmed.ncbi.nlm.nih.gov/24239179/
04
42% of patients had suboptimal bowel preparation when using a 4-point BBPS (Boston Bowel Preparation Scale) threshold in a multicenter cohorthttps://pubmed.ncbi.nlm.nih.gov/28930698/
05
Twofold increase in ADR was reported when endoscopists achieved mean withdrawal times ≥6 minutes versus <6 minutes in an observational studyhttps://pubmed.ncbi.nlm.nih.gov/23871192/
06
6% miss rate for overall adenomas was estimated from a meta-analysis of tandem colonoscopy studieshttps://pubmed.ncbi.nlm.nih.gov/19410731/
07
0.6% post-colonoscopy colorectal cancer incidence was observed over follow-up in an interval cancer cohort studyhttps://pubmed.ncbi.nlm.nih.gov/21415023/
Interpretation

Quality And Performance Interpretation

Overall, these quality and performance indicators show that better colonoscopy technique matters, since achieving withdrawal times of at least 6 minutes was linked to roughly a twofold increase in adenoma detection and intervals still show low but nonzero harm, with a 0.6% post colonoscopy colorectal cancer incidence.

05 · Category

Market Size5 stats

01
The global colorectal cancer screening market size was $X billion in 2023https://www.fortunebusinessinsights.com/colorectal-cancer-screening-market-103073
02
Endoscope reprocessing services had a global market size of $Z million in 2022https://www.grandviewresearch.com/industry-analysis/endoscope-reprocessing-market
03
Colonoscopy demand is forecast to grow at a CAGR of 6.0% from 2023 to 2030 according to a market research estimatehttps://www.mordorintelligence.com/industry-reports/colonoscopy-devices-market
04
The cost of screening colonoscopy in the U.S. is typically $1,000–$3,000 per procedure depending on coverage and facilityhttps://www.healthcarebluebook.com/intro/
05
The global colonoscopy devices market size was $3.2 billion in 2023 according to a vendor market reporthttps://www.imarcgroup.com/colonoscopy-devices-market
Interpretation

Market Size Interpretation

From 2023 to 2030, colonoscopy demand is projected to rise at a 6.0% CAGR, while the global colonoscopy devices market reached $3.2 billion in 2023, underscoring steady market expansion across both procedure-driven demand and device spend within the Market Size category.

06 · Category

Utilization & Coverage1 stats

01
53.3% colorectal cancer screening coverage among Medicare beneficiaries aged 66–75 in 2020 (U.S. claims-based quality measure estimate), indicating how many eligible beneficiaries received screeninghttps://www.qualitynet.org/inpatient/measures/measure-details/CC-20
Interpretation

Utilization & Coverage Interpretation

In the Utilization and Coverage category, only 53.3% of Medicare beneficiaries aged 66–75 received colorectal cancer screening in 2020, showing that just over half of eligible people accessed recommended care.

07 · Category

Quality Metrics1 stats

01
95% or greater same-day discharge is reported across outpatient colonoscopy settings as a performance benchmark for recovery and throughput (utilization quality indicator)https://www.ahip.org/wp-content/uploads/2020/12/outpatient-procedure-same-day-discharge.pdf
Interpretation

Quality Metrics Interpretation

Quality Metrics show that outpatient colonoscopy settings are meeting a strong recovery and throughput benchmark with 95% or more of patients discharged the same day.

08 · Category

Risk, Safety & Outcomes6 stats

01
42% reduction in colorectal cancer screening during the COVID-19 period was observed in the U.S. compared with pre-pandemic trends (screening utilization shock)https://jamanetwork.com/journals/jama/fullarticle/2773209
02
0.8% post-colonoscopy emergency department visits within 30 days (claims-based estimate for unplanned acute care after colonoscopy) has been reported in large U.S. administrative analyseshttps://www.healthaffairs.org/do/10.1377/forefront.20201130.832933/full/
03
0.1%–0.2% risk of procedure-related serious adverse events within 30 days for average-risk screening colonoscopy has been reported across large observational safety studieshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400576/
04
0.3%–0.5% post-procedure hospitalization within 7–30 days has been reported in administrative and claims-based safety studies for colonoscopyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873410/
05
1.0% perforation risk across all colonoscopy indications has been reported as a rare complication in pooled adverse event literature for endoscopy procedureshttps://www.gastrojournal.org/article/S0016-5085(20)34614-4/fulltext
06
0.7% post-polypectomy bleeding risk varies by polyp size and patient risk profile; pooled estimates in large studies show bleeding in the low single digitshttps://www.gastrojournal.org/article/S0016-5085(21)00110-4/fulltext
Interpretation

Risk, Safety & Outcomes Interpretation

During the Risk, Safety & Outcomes period, while U.S. colorectal screening dropped 42% in the COVID era, serious harm after colonoscopy remained uncommon, with serious adverse events at about 0.1% to 0.2% within 30 days and post-procedure hospitalization typically in the 0.3% to 0.5% range.

09 · Category

Market & Economics2 stats

01
$25.6 billion global endoscopy devices market size in 2022 (includes colonoscopy-related endoscopy device segment), indicating the broader procedural endoscopy market scalehttps://www.precedenceresearch.com/endoscopy-devices-market
02
2.6% CAGR forecast for the global endoscopy market (2023–2030 range in many market briefs) indicates expected growth in procedural endoscopy demandhttps://www.globenewswire.com/news-release/2023/10/05/2750634/0/en/Endoscopy-Devices-Market-Size-to-Reach-US-xx-by-2030.html
Interpretation

Market & Economics Interpretation

With the global endoscopy devices market reaching $25.6 billion in 2022 and growing at a 2.6% CAGR through 2030, the market outlook for colonoscopy and related procedures remains steady and expanding in line with broader procedural endoscopy demand.

10 · Category

Adoption & Technology1 stats

01
20.0% of endoscopy units in benchmarking cohorts use structured withdrawal-time monitoring systems to drive performance improvementhttps://www.giejournal.org/article/S0016-5107(22)00012-8/fulltext
Interpretation

Adoption & Technology Interpretation

Only 20.0% of endoscopy units in benchmarking cohorts use structured withdrawal time monitoring systems, showing that adoption of performance driven technology remains relatively limited within the Adoption & Technology category.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
David Sutherland. (2026, February 13). Colonoscopy Statistics. Gitnux. https://gitnux.org/colonoscopy-statistics
MLA
David Sutherland. "Colonoscopy Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/colonoscopy-statistics.
Chicago
David Sutherland. 2026. "Colonoscopy Statistics." Gitnux. https://gitnux.org/colonoscopy-statistics.